Oxford Nanopore price target raised to GBP2.10 from GBP1.90 at Deutsche Bank

Deutsche Bank raised its price target for Oxford Nanopore (LON:ONT) to GBP2.10 from GBP1.90, maintaining a Buy rating. The firm cited the company's "de-risked" fiscal year 2025 outlook, superior growth potential, sequential reduction in EBITDA losses, and improved cash flow, positioning it as a "UK champion with disruptive technology" outperforming peers. Despite trading at a premium ~6x EV/Sales for FY2025 compared to sequencing peers, Deutsche Bank justifies this valuation by Oxford Nanopore's robust growth trajectory, underpinning its continued positive outlook.

Analysis

Deutsche Bank has reiterated its conviction in Oxford Nanopore (LON:ONT) by raising its price target to GBP2.10 from GBP1.90 while maintaining a 'Buy' rating. The bank's rationale is anchored in the view that management's prudent approach has 'de-risked' the outlook for fiscal year 2025. Key fundamental improvements underpinning this confidence include a sequential reduction in EBITDA losses and enhanced cash flow, positioning the company's growth well ahead of its peers. Despite trading at a premium valuation of approximately 6 times enterprise value to FY2025 sales, compared to the 4-5 times multiple for its sequencing peers, Deutsche Bank justifies this premium by citing Oxford Nanopore's 'superior growth potential'. This perspective frames the company as a 'UK champion with disruptive technology' that is successfully translating its innovation into tangible financial progress.

Key Decisions for Investors

• Investors should view the upgraded price target and reaffirmed 'Buy' rating from Deutsche Bank as a strong validation of Oxford Nanopore's growth narrative and improving profitability path.
• The premium valuation at ~6x forward EV/Sales requires careful consideration, as it is predicated on the company's ability to maintain its superior growth trajectory relative to peers; any slowdown could challenge this valuation.
• Monitor upcoming interim results closely for continued evidence of sequential EBITDA loss reduction and cash flow improvement to confirm that the 'de-risked' FY2025 outlook remains on track.